Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation.
BACKGROUND
Cardiac death is the leading cause of mortality associated with sarcoidosis in Japan. However, the involvement of sarcoidosis infiltration often remains undetected. Recently, late gadolinium enhancement with cardiovascular MRI (LGE-CMR) imaging has been introduced for the detection of myocardial infiltrative disease, as it enables the detection of even minor myocardial damage. We investigated the incidence and prognostic value of LGE-CMR in patients with extracardiac sarcoidosis without cardiac manifestations.


METHODS
Sixty-one consecutive patients who met the histologic and clinical criteria for sarcoidosis, and who did not have signs or symptoms of cardiovascular involvement, were prospectively recruited. LGE-CMR was performed at the time of enrollment, and patients were classified into positive or negative late gadolinium enhancement groups based on the findings. The study end point was a composite of all-cause death, symptomatic arrhythmia, and heart failure necessitating admission.


RESULTS
Patients were predominantly middle aged (57 ± 15 years) and female (66%), and most had stable disease activity that did not require treatment with immunosuppressants. LGE-CMR detected cardiac involvement in eight patients (13%). Interventricular septal thinning detected by echocardiography was an independent predictor of LGE-CMR-detected cardiac involvement. During the follow-up period of 50 ± 12 months, no significant difference in adverse events was noted between patients in the LGE-CMR-positive and LGE-CMR-negative groups.


CONCLUSIONS
LGE-CMR detected cardiac involvement in 13% of patients with sarcoidosis without cardiac manifestation, but both patients with and without LGE had relatively low event rates.


BACKGROUND
Japan Primary Registries Network; No.: UMIN000001549; URL: www.umin.ac.jp.
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka. Electronic address: nagai@ncvc.go.jp.
Toshiyuki
T
Nagai
Department of Cardiology, Keio University School of Medicine, Tokyo.
Shun
S
Kohsaka
Department of Diagnostic Radiology, Keio University School of Medicine, Tokyo.
Shigeo
S
Okuda
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka.
Toshihisa
T
Anzai
Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan.
Koichiro
K
Asano
Department of Cardiology, Keio University School of Medicine, Tokyo.
Keiichi
K
Fukuda
D000328:Adult; D000368:Aged; D009202:Cardiomyopathies / Q000175:diagnosis*; D003287:Contrast Media; D004452:Echocardiography; D005260:Female; D005500:Follow-Up Studies; D005682:Gadolinium; D006321:Heart / Q000503:physiopathology*; D006331:Heart Diseases / Q000175:diagnosis*; D006801:Humans; D015994:Incidence; D019028:Magnetic Resonance Imaging, Cine; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology; D011379:Prognosis; D011446:Prospective Studies; D012044:Regression Analysis; D018570:Risk Assessment; D012507:Sarcoidosis / Q000175:diagnosis* / Q000503:physiopathology; D016019:Survival Analysis
D003287:Contrast Media; D005682:Gadolinium